Context: Although 60% of papillary thyroid carcinomas are BRAF V600E mutant (PTC V600E ), the increased aggressiveness of these cancers is still debated.
Brussels, Belgium
Context: Although 60% of papillary thyroid carcinomas are BRAF V600E mutant (PTC V600E ), the increased aggressiveness of these cancers is still debated.
Objective: For PTC V600E we aimed to further characterize the extent of the stroma and its activation, the three-dimensional (3D) tumor-stroma interface, and the proliferation rates of tumor and stromal fibroblasts.
Design: We analyzed exomes, transcriptomes, and images of 364 papillary thyroid carcinoma (PTCs) from The Cancer Genome Atlas (TCGA), including 211 PTC
V600E
; stained 22 independent PTCs for BRAF V600E and Ki67; sequenced the exomes and stained BRAF V600E in 5 primary tumor blocks and 4 nodal metastases from one patient with PTC
; and reconstructed the 3D volumes of one tumor and one metastatic block at histological resolution.
Results: In TCGA, BRAF V600E was associated with higher expression of proliferation markers and lower expression of thyroid differentiation markers, independently of tumor purity. Moreover, PTC
, in line with their overall lower purity, also had higher expression of fibroblast-and T cell-associated genes and presented more fibrosis. Tumor cells that appeared disconnected on two-dimensional histological slices were revealed to be part of a unique tumor component in the 3D reconstructed microvolumes, and they formed a surprisingly complex connected space, infiltrating a proliferative stroma. Finally, in our PTC set, both stromal fibroblasts and tumor cells presented higher proliferation rates in PTC T o focus on informative sequencing data, most oncogenomic studies reject samples with low tumor cell content based on pathology examination. Nevertheless, low-purity samples routinely end up being sequenced and in most cases are deemed useless for further analysis. This paper stems from the sequencing of such series of tumor regions, originally collected for a study of the intratumor and interfoci heterogeneity in papillary thyroid carcinoma (PTC). We reasoned that further investigation of the underlying tumor morphology could shed light on the contribution to tumor expansion of noncancerous cells.
The shape of the tumor mass is important because it defines the contact area with the stroma, where features of aggressiveness, such as invasiveness and increased proliferation, are observed (1) . Some of these carry prognostic information in various cancer types, such as oral cancers (2) . In fact, together with the morphology of the tumor cells, the morphology of the tumor mass relates to the mode of metastatic dissemination (3). Cancerassociated fibroblasts (CAFs) pull on tumor cells, generating tumor elongations (4) .
Interestingly, many PTCs present poorly defined boundaries (5). Liu et al. (6) showed an association between PTC recurrence and presence of isolated clusters of cells and loss of cell polarity [i.e., two features of epithelial-to-mesenchymal transition (EMT)]. Moreover, microPTC V600E (PTC ,1 cm, with BRAF V600E mutation)
seemed to present invasive fronts with a more complex architecture, encompassing markedly invasive contours, when compared with microPTC WT (7) . Isolated clusters of tumor cells at the invasive front could be interpreted as the consequence of EMT, followed by a return to the epithelial state (1) . Alternatively, these isolated islands of cells observed on two-dimensional (2D) slices could also belong to the same connected three-dimensional (3D) tumor volume, implying branching patterns drifting from an ellipsoid.
So far, 3D tumor volumes have been mostly acquired by medical imaging techniques, such as computed tomography and magnetic resonance imaging, common in the field of radiomics (8) . These technologies, which operate at macroscopic scale, typically yield ellipsoidshaped tumor volumes with fingering patterns. In this context the tumor-stroma interface is implicitly assumed to sit on an ellipsoid periphery. For example, Vasko and collaborators (9) analyzed differential expression between peripheral and central parts of PTC, suggesting a higher degree of EMT at the periphery. The assumption that the tumor-stroma contact surface is ellipsoid, however, has never been demonstrated at the fine scale relevant to cell-to-cell contact.
Upon zooming in on the invasive front with higherresolution imaging, the observed tumor-stroma contact area may increase quite a lot, akin to coastline lengths at different magnifications in the coastline paradox (10) . The fractal dimension measures the increase in tumorstroma contact area in proportion to the magnification. At histological resolution, the morphology of the tumor mass has been described as complex and the fractal dimension was linked to prognosis (11) . In colorectal carcinoma, tumor budding is a complex pattern whereby isolated clusters of cells at the invasive front have undergone EMT, and it has been associated with worse prognosis (12) . In our study, we explored the 3D shape of the tumor/stroma contact area at a histological scale.
PTCs represent ;80% of all thyroid cancers (13) and, given the rapidly increasing incidence of microPTC, mostly due to earlier diagnosis, thyroid cancer could become the fourth most diagnosed cancer in the United States by 2030 (14) .
A recent study by The Cancer Genome Atlas (TCGA) (15) identified driver mutations in 96.5% of 496 PTCs. In line with previous studies, PTC progression was essentially driven by constitutive activation of the mitogenactivated protein kinase (MAPK) pathway, with the most frequent mutations found in the BRAF, RAS, and RET genes (15, 16) . BRAF V600E was the most frequent mutation, detected in ;60% of PTCs (15, 17) .
Although several studies have found an association of BRAF V600E with clinical features of aggressiveness and bad prognosis in PTC (7, 18) , this has often been disputed (19) . Most notably, BRAF V600E was not associated with distant metastasis (20, 21) . However, in PTC V600E presenting poorly differentiated or undifferentiated areas, it was consistently detected in both regions, suggesting a role in the progression from PTC to the aggressive undifferentiated cancers (17, 22) . Here, the analysis of TCGA histological images and genomic and transcriptomic data shows that our low-purity multiregion PTC is part of a continuum of PTC structures in which BRAF V600E PTC stands out with strong CAF activation, lower tumor cell purity, dedifferentiation of tumor cells, and a high proliferation rate in both the tumor cell and the CAF compartments.
Materials and Methods

PTC V600E case description
A 51-year-old woman diagnosed with a bilateral PTC (right lobe: 0.6 cm; left lobe: 2.8 cm) and concurrent metastatic involvement of the lymph nodes (stage IVA, pT3N1b) was treated with total thyroidectomy and lymphadenectomy (five nodal metastases in the recurrent and mediastinal areas). Iodine-131 radiotherapy was administered 1 month after surgery. Twelve months after thyroidectomy, nodal recurrences were removed (four nodal metastases from the left cervical, three of which were included in the study: M2, M3, and M4). First histopathological examination revealed a classic PTC in a goiter context and suggested a tumor cell fraction .70%.
Tissue samples
For immunohistochemistry (IHC) and exome analyses, tumor and normal thyroid tissues were obtained from the Jules Bordet Institute tissue bank (Brussels, Belgium). We included four foci of the primary PTC from the left lobe (T1 to T4), one from the right lobe (T5), and four nodal metastases (M1 to M4). Noncancerous adjacent tissues from the tumor (N1 to N3), the lymph node, and a blood sample were taken as controls. Immediately after surgery, tissues were macro-dissected in several blocks. Each block was cut into two equal parts. One part was embedded in paraffin for histological analyses, and the other part snap-frozen in liquid nitrogen and stored at 280°C.
Independent PTC set
Twenty-two additional PTCs from Jules Bordet Institute were taken as independent set for hematoxylin and eosin, Ki67, and BRAF staining. They were selected on the basis of sample age and contained 13 BRAF-mutant and 9 BRAF-wild-type (WT; mostly classical PTC variant; Supplemental Table 1 ).
DNA sequencing
DNA from tumor and normal thyroid tissues was extracted by using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. DNA concentrations were spectrophotometrically quantified, and integrity was measured by using an automated gel electrophoresis system (Experion; Bio-Rad, Hercules, CA). Exome DNA sequencing was performed with the Nextera Rapid Capture Expanded exome kit and material was sequenced on the Illumina HiSEquation 2000 platform (Illumina Inc., San Diego, CA) using 100-base paired-end reads, for a yield of ;180 million reads per sample (analyses in Supplemental Material). 
3D reconstitution
For two of the paraffin tumor blocks, T1 and M1, .100 adjacent slices were cut and stained for BRAF V600E protein. These images were used to reconstruct the associated 3D volumes of the tumor stained for the mutated protein. 3D reconstitution was obtained by using BioVis3D (Montevideo, Uruguay). Images of adjacent slices were manually aligned. Then, on each slice, contours of the stained tumor parts were manually created and were linked, divided, or merged from slice to slice. Finally, BioVis3D rendered a 3D model of these connected 2D contours (Supplemental Video 1).
Ki67 quantification
For each block, proliferation rates were calculated on scanned images stained for Ki67 by counting the Ki67-stained nuclei and comparing with the nonstained nuclei (23) . Ki67 indices were computed separately in multiple regions for the CAFs and follicular parts. This approach provided average proliferation rates and associated estimates of the measurement error across the slice (Supplemental Material; Supplemental Fig. 1 ).
Data availability
Sequence data are available in the European GenomePhenome Archive under accession number EGAB00000001141. All scripts and additional data are available upon request.
Study approval
The patient gave written informed consent. 
Results
Multiregion sequencing and quantitative imaging reveal low cellularity in ∼30% of PTC V600E escaping pathology examination We performed multiregion exome sequencing of a BRAF V600E PTC (Fig. 1A and 1B) . The regions included five primary-tumor blocks, four nodal metastases, and three histologically normal thyroid blocks and a normal lymph node.
The allelic ratio of BRAF V600E estimated from sequencing data ranged from 0% to 30% (Fig. 1C) . Quantitative analysis of Sanger sequencing technically validated these allelic ratios (Fig. 1C) . Such low ratios could have resulted from low tumor cell fractions, copy number aberration, or subclonal BRAF V600E mutations. Subclonality of the mutation was suggested in previous studies (24, 25) . We compared in each region the allelic ratios of BRAF V600E and of all other mutations (Fig. 1F) .
In all regions but one, BRAF V600E was among the mutations with the largest allelic ratios. This ruled out the subclonality of BRAF V600E in our samples. Paraffin-embedded slices immediately adjacent to each one of the tumor regions used for exome sequencing were stained with an antibody specific of BRAF V600E ( Fig. 1A and 1B; Fig. 2A ). Taking advantage of the distinctive hue of stained cells, we estimated the areas occupied by BRAF V600E tumor cells and by the entire tumor slice. We then compared the tumor cell area ratio to the tissue fraction estimated from their region-matched BRAF V600E allelic ratio. They were highly consistent ( Fig. 1D and 1E ), strongly supporting a low ratio of tumor cells within the overall tumor mass. Surprisingly, prior pathology review guaranteed a cellularity .70%. As it turned out, the vast fibrotic regions present in the tumor mass were unexpectedly densely cellular.
To address how commonly cellularity is underestimated, we obtained allelic ratios for the mutation corresponding to BRAF V600E , as measured from exome sequencing of 211 PTCs from the TCGA (15) (Fig. 1G) . Our tumor regions were on the very low end of the TCGA purity range but not below it. Moreover, the a priori pathologic purity threshold for the inclusion of PTC samples in the TCGA was 60%, whereas the purities computed in silico a posteriori were ,60% for around one third of the samples (Supplemental Fig. 2) . We concluded that tumor cell purity is low in a nontrivial fraction of PTCs and that it is often underestimated during pathology examination.
3D histological-scale reconstruction of low-purity PTC V600E blocks reveals dense connected fractal-like meshes of tumor cells, with an extensive contact surface with the stroma In all regions, BRAF V600E staining revealed isolated patches of tumor cells embedded within an extensive stroma, constituted in the majority by fibroblasts (Fig. 2A) . Cells that appear to be isolated in two dimensions, however, could turn out to be part of the same tumor mass when observed in 3D.
A protocol was devised to reconstruct and visualize the geometry of the tumor cell mass in a 3D manner (Supplemental Video 1). This 3D reconstruction at histological scale was applied to the nodal metastasis block M1 and the primary tumor block T1 ( Fig. 2A and 2B ; Supplemental Video 2) of~1 mm 3 each. For block M1, no isolated island of tumor cells was found in the tumor volume reconstructed over a depth of 200 mm (i.e., all cells were part of a single connected component). For block T1, the number of disconnected tumor cell clusters was reduced from a dozen in the 2D slice to an upper bound of two in the 200-mm-deep 3D microvolume. This strongly suggested that the tumor cells within a region formed a single connected component.
Interestingly, the 3D volumes departed drastically from any compact ellipsoidal shape. Tumor cells formed a complex volume deeply embedded within the CAFs. Instead of a tumor with an invasive front in contact with the stroma and inner tumor cells in contact mostly with other tumor cells, we observed that most tumor cells were in direct contact with, or nearby, the stroma.
CAFs and cancer cells proliferate at similar rates in PTC
The results of previous sections raised the question of which cell types from the mixture of stromal and tumor cells drive tumor growth.
We performed Ki67 staining on our regions and compared proliferation rates of normal stroma, stroma adjacent to tumor, noncancerous follicular thyroid cells, and tumor cells (Fig. 3A) . As expected, proliferation rates were higher in tumor blocks than normal thyroid blocks. Primary tumor regions and metastases had similar proliferation rates. Intriguingly, the proliferation rate of CAFs was not lower than that of follicular thyrocytes.
To generalize this finding, we measured Ki67 indices in the stromal and tumor compartments of 22 independent PTC, including 13 BRAF V600E and 9 BRAF WT tumors (Fig. 3B) . Importantly, these samples were not selected for specific tumor cell purity. For each tumor, one slice was stained for Ki67. The ratio of Ki67-stained nuclei for tumor cells was not higher than for CAFs, suggesting that the density of cycling cells in the fibrous stroma was high.
BRAF V600E is associated with a desmoplastic phenotype, high proliferation rate, and dedifferentiation We combined image, genomic, and transcriptomic analyses of the 496 PTCs from the TCGA (15) to further characterize the phenotype of PTC V600E and how it relates to the relative sizes of the tumor and stromal compartments.
In the TCGA cohort, we downloaded the PTC histological hematoxylin and eosin-stained slide images from the TCGA cancer digital archives (http://cancer. digitalslidearchive.net). Because fibrosis presented a distinctive color hue (Fig. 4A) , it was possible to automatically estimate fibrotic content as the ratio of the fibrotic areas to the total tumor area. Fibrotic content was higher in PTC V600E than in other PTCs (Fig. 4B) . RASmutated tumors had the least fibrous tissue.
The area of the fibrotic regions does not necessarily reflect the number of cells within these regions. We therefore investigated tumor purity of TCGA PTC (15) , as measured in silico by the ABSOLUTE method (26) . Purity was lower in BRAF V600E PTCs than in BRAF
WT
PTCs and especially higher in RAS-mutated PTCs (Fig. 4C) . To further define the activity of these fibrotic regions, we corrected the fibrosis ratios for the purity of the samples by using a robust linear model (Fig. 4D) . The association of BRAF V600E with fibrosis remained highly significant. Taken together with the Ki67 data from our cohort, these results suggest that PTC V600E is associated with a desmoplastic phenotype: These tumors include more fibroblasts, which proliferate more and produce more fibrosis.
To gain a broader view of the phenotype of individual PTCs from the TCGA, we derived five gene expression signatures capturing different aspects of PTC biology. Two were derived by following the procedure of the original TCGA study, including genes associated with thyroid differentiation and with the BRAF-RAS axis (15) . We also derived three additional signatures for fibroblasts, T cells, and proliferation. Associations between BRAF mutational status and each one of the five gene expression signatures were statistically significant (Mann-Whitney tests; false discovery rates , 10 25 separately from normal tissues along axes of thyroid differentiation, proliferation, and BRAF-RAS expression differences. As expected from the TCGA study, they further separated from BRAF WT PTCs along the vector representing thyroid differentiation and BRAF-RAS expression differences, but also along the vectors standing for fibroblasts, lymphocytes, and proliferation (Fig. 4F) . Interestingly, the fibroblasts and proliferation axes were strongly associated in these PTCs, which was reflected in their almost identical directions on Fig. 4F . Together the higher proliferation and dedifferentiation indices of PTC V600E point to a more aggressive phenotype.
Discussion
Textbooks and medical imaging suggest that cancers expand as a compact nearellipsoid ball with an inner core and an invasive front in contact with noncancerous tissues. At histological scale, the 3D reconstruction of our low-purity PTC revealed a morphology departing radically from this archetype. Far from an ellipsoid, this morphology would be better depicted as a branching fractal-like aggregate of cancer cells deeply embedded within the stroma. In this morphology, the concepts of inner core and invasive front break down because all tumor cells are within short distance from the stroma. The 3D reconstructions also suggested that tumor cells belonged to a single connected component within the ;1-mm 3 volumes investigated. Thus, all cancer cells were in contact with or close to both stromal and cancer cells.
CAFs lead the collective invasion of carcinoma cells (4). The same phenomenon could be active in PTC, as elongating patterns of neoplastic cells into nonneoplastic cells were described in microPTC (7). Transforming growth factor-b (TGF-b) signaling was involved in many tumor-stroma interactions involving EMT, proliferation, and activating signals. PTC cells could send signals to the surrounding stroma, potentially involving TGF-b1 (27) , with increased response or signal in PTC V600E .
Our analysis also argues against the textbook view that tumor expansion is driven by cancer cell proliferation alone. Cancer cells represented a small fraction of the total number of cells making the tumor mass, ,10% in several regions. In such circumstances, we ask how the tumor still reaches a clinically detectable volume and whether excess proliferation is an exclusive property of the tumor cells. We measured proliferation rates in the tumor and stromal compartments of our original low-purity regions and associated normal-thyroid tissues and in an independent series of PTCs. In contrast to the former, the latter series was not selected for specific purity or fibrotic content. Proliferation was higher in tumor than in normal tissues for both compartments. Our estimations based on Ki67 staining suggested that CAFs proliferate faster than tumor cells (Fig. 3B) . However, unstained nuclei are more easily detected in cancer cells than in fibroblasts, which may bias any direct comparison of proliferation between these compartments. At this point, we can assert only that the proliferation of fibroblasts is increased in PTCs compared with normal thyroid. Further research is needed to quantify precisely the relative contribution of both compartments to tumor expansion.
Pathology examination initially suggested that our samples had purities .70%. Subsequent sequencing and computational analyses demonstrated that they were much lower. Fibrotic regions, it turned out, were more cellular than expected. Similarly, inclusion of samples in TCGA thyroid cancer dataset required a purity .60% upon pathology review, but subsequent sequencing and analysis demonstrated that one third of the samples did not meet this criterion. Purity could be underestimated in other studies. Our samples were at the lower end of the purity spectrum, but they were not unique: 3.5% of the 342 TCGA samples analyzed had purities ,25%. Given that the inclusion criteria of the TCGA introduced a selection bias toward higher purity, 25% would be an upper-bound estimate of the true purity range of PTC. Incidentally, the association of low purity with BRAF V600E implies that BRAF V600E incidence could also be underestimated in TCGA and possibly other studies. This observation generalizes to any confounding genetic factor correlated with purity.
To interpret the genome-derived purities, we also analyzed the fibrotic content of TCGA PTC from tumor images and the expression of fibroblast-associated genes. We observed a wide spectrum of purity, fibrosis, and fibroblast gene expression scores. Within this spectrum, nearly all RAS-mutated PTCs had highest purity, lower fibrosis, and lower fibroblast gene expression. By contrast, other tumors, most of them harboring BRAF V600E , covered the entire range of scores, including a sizable fraction of tumors with low purity, high fibrosis, and high fibroblast gene expression. Previous literature pointed to a role for CAF in PTC. In one study, PTC V600E showed more fibrosis/desmoplasia and infiltrative growth (28) . In another study, microPTC V600E also had more fibrosis content (7) . Interestingly, both the image-derived fibrotic and the fibroblast gene expression scores were associated with BRAF V600E independently of purity in our analyses.
This suggests that the mutational status of PTC is associated with fibrosis but also the density of CAF and their activation state. We showed that PTC V600E have a higher expression of proliferation-associated genes and of the Ki67 protein and lower expression of thyroid-differentiation genes. Potential links have been described between aggressiveness and tumor-stroma crosstalk in PTC (29) . For example, PTC V600E could be more invasive because of decreased CDH1 expression (30) and more susceptible to TGF-binduced EMT through an MAPK-dependent process (31) . Furthermore, the cross-talk involving TGF-b at the invasive front led to more aggressive and refractory PTC V600E in PCCL3 cells (32) . CAFs and endothelial cells may also express EMT markers (33) . Given the high fibroblast content of PTC V600E revealed here, expression of EMT markers in bulk tissue profiling should be interpreted with caution. Altogether, our results depict a more aggressive phenotype of PTC V600E , aided by extensive, more active and proliferative CAF (i.e., a higher desmoplastic reaction associated with BRAF V600E in PTCs). These tumors could in theory be treated accordingly. Approved drugs targeting the BRAF-mutated pathway would represent good candidates. Although they are still at an early stage of clinical assessment in thyroid cancer, PTCs might respond to a lesser degree to BRAF inhibitors compared with melanoma and other cancer types with MAPK pathway activation (34) . Interestingly, higher CAF content and a stiffer extracellular matrix protect melanoma V600E cells against BRAF-pathway inhibitors (35) . The higher density and activation of CAFs in PTCs uncovered here may similarly induce resistance (35) . Hence, our results would be compatible with improved treatment response via combination of ECM and BRAF inhibitors in PTC V600E (35) . 
